PL2912041T3 - Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE - Google Patents

Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE

Info

Publication number
PL2912041T3
PL2912041T3 PL13785730T PL13785730T PL2912041T3 PL 2912041 T3 PL2912041 T3 PL 2912041T3 PL 13785730 T PL13785730 T PL 13785730T PL 13785730 T PL13785730 T PL 13785730T PL 2912041 T3 PL2912041 T3 PL 2912041T3
Authority
PL
Poland
Prior art keywords
tetrahydropyrrolothiazine
derivatives
bace inhibitors
bace
inhibitors
Prior art date
Application number
PL13785730T
Other languages
English (en)
Inventor
Fionna Mitchell Martin
Dustin James Mergott
William Martin Owton
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL2912041T3 publication Critical patent/PL2912041T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13785730T 2012-10-26 2013-10-17 Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE PL2912041T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718728P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
PL2912041T3 true PL2912041T3 (pl) 2017-06-30

Family

ID=49515508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13785730T PL2912041T3 (pl) 2012-10-26 2013-10-17 Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE

Country Status (17)

Country Link
US (1) US9328124B2 (pl)
EP (1) EP2912041B1 (pl)
JP (1) JP6243921B2 (pl)
CN (1) CN104755484B (pl)
CA (1) CA2886507C (pl)
CY (1) CY1118623T1 (pl)
DK (1) DK2912041T3 (pl)
ES (1) ES2616835T3 (pl)
HR (1) HRP20170025T1 (pl)
HU (1) HUE031764T2 (pl)
LT (1) LT2912041T (pl)
ME (1) ME02576B (pl)
PL (1) PL2912041T3 (pl)
PT (1) PT2912041T (pl)
RS (1) RS55561B1 (pl)
SI (1) SI2912041T1 (pl)
WO (1) WO2014066132A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366855B (es) 2013-03-01 2019-07-26 Amgen Inc Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法
TWI684452B (zh) * 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
ES2910367T3 (es) 2016-12-15 2022-05-12 Amgen Inc Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
US10889579B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Thiazine derivatives as β-secretase inhibitors and methods of use
AU2017376441B2 (en) 2016-12-15 2021-10-14 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
CN106632001A (zh) * 2016-12-28 2017-05-10 山东诚汇双达药业有限公司 一种4‑(溴乙酰基)吡啶氢溴酸盐的制备方法
CN110452179A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054617A1 (es) 2005-06-14 2007-07-04 Schering Corp Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
AR072952A1 (es) 2008-04-22 2010-10-06 Schering Corp Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
US20110207723A1 (en) 2008-09-30 2011-08-25 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
GB201212871D0 (en) * 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
CN104755484B (zh) 2016-02-17
EP2912041B1 (en) 2016-12-14
CA2886507C (en) 2016-09-20
ES2616835T3 (es) 2017-06-14
HRP20170025T1 (hr) 2017-03-10
CA2886507A1 (en) 2014-05-01
DK2912041T3 (en) 2017-02-27
EP2912041A1 (en) 2015-09-02
WO2014066132A1 (en) 2014-05-01
US9328124B2 (en) 2016-05-03
ME02576B (me) 2017-06-20
CN104755484A (zh) 2015-07-01
US20150232483A1 (en) 2015-08-20
HUE031764T2 (en) 2017-07-28
CY1118623T1 (el) 2017-07-12
JP2015535247A (ja) 2015-12-10
PT2912041T (pt) 2017-02-13
SI2912041T1 (sl) 2017-02-28
RS55561B1 (sr) 2017-05-31
JP6243921B2 (ja) 2017-12-06
LT2912041T (lt) 2017-03-10

Similar Documents

Publication Publication Date Title
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201409422B (en) Benzimidazole-proline derivatives
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
ZA201408876B (en) Pyrrolotriazinone derivatives
PL2912041T3 (pl) Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HUE051078T2 (hu) 4-karboxamido-izoindolinone származék mint szelektív parp-1 inhibitor
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors